Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma

This study aims to systematically evaluate the safety and efficacy of adalimumab combined with paclitaxel, carboplatin, and short-course radiotherapy in the neoadjuvant treatment of esophageal squamous cell carcinoma.

Trial Details

NCT ID
NCT07595770
Phase
PHASE2
Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • • Adebrelimab and nab-paclitaxel, carboplatin in Combination With radiotherapy
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • \- 1. Provided informed consent and sign the informed consent form;
  • 2\. Male or female, Aged 18-75 years (counted on the date of signing informed consent);
  • 3\. Pathological confirmed ESCC;
  • 4\. Patients assessed by thoracic oncologists as resectable without distant metastasis

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →